We are live on ! Find out more
BTAI icon

BioXcel Therapeutics
BTAI

96 hedge funds and large institutions have $274M invested in BioXcel Therapeutics in 2022 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 34 increasing their positions, 28 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 12

21% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 28

3% more funds holding

Funds holding: 93 → 96 (+3)

0.18% less ownership

Funds ownership: 3.11% → 2.93% (-0.18%)

3% less capital invested

Capital invested by funds: $283M → $274M (-$9.19M)

21% less call options, than puts

Call options by funds: $3.46M | Put options by funds: $4.4M

Holders
96
Holders Change
+3
Holders Change %
+3.23%
% of All Funds
1.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
34
Reduced
28
Closed
12
Calls
$3.46M
Puts
$4.4M
Net Calls
-$939K
Net Calls Change
-$2.86M

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$4.86M
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$1.74M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.47M
4
State Street
State Street
Massachusetts
+$1.01M
5
Jane Street
Jane Street
New York
+$988K

Top Sellers

Rank Fund Capital Flow
1
AllianceBernstein
AllianceBernstein
Tennessee
-$26.6M
2
Citigroup
Citigroup
New York
-$1.13M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$968K
4
WMSA
Weiss Multi-Strategy Advisers
New York
-$609K
5
Morgan Stanley
Morgan Stanley
New York
-$429K
Name Holding Trade Value Shares
Change 		Change in
Stake
N
26
Nuveen
North Carolina
$958K -$58.3K -201 -5%
GCM
27
Graham Capital Management
Connecticut
$897K +$543K +1,875 +232%
AllianceBernstein
28
AllianceBernstein
Tennessee
$865K -$26.6M -91,712 -97%
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
29
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$836K – – –
ACA
30
Apis Capital Advisors
New York
$836K +$725K +2,500 New
HWAM
31
Hennion & Walsh Asset Management
New Jersey
$736K +$13K +45 +2%
DC
32
Davenport & Co
Virginia
$704K -$18.3K -63 -3%
CL
33
CSS LLC
Illinois
$604K -$44.1K -152 -8%
AA
34
ALPS Advisors
Colorado
$601K -$65.5K -226 -11%
PP
35
PDT Partners
New York
$586K +$508K +1,752 New
Wellington Management Group
36
Wellington Management Group
Massachusetts
$552K +$31.9K +110 +7%
Deutsche Bank
37
Deutsche Bank
Germany
$514K -$72.5K -250 -14%
California State Teachers Retirement System (CalSTRS)
38
California State Teachers Retirement System (CalSTRS)
California
$507K -$29K -100 -6%
ACM
39
ACT Capital Management
Pennsylvania
$418K – – –
KCM
40
Knoll Capital Management
Florida
$418K – – –
Millennium Management
41
Millennium Management
New York
$405K +$2.61K +9 +0.7%
Truist Financial
42
Truist Financial
North Carolina
$403K +$349K +1,205 New
Renaissance Technologies
43
Renaissance Technologies
New York
$393K +$341K +1,175 New
TAM
44
Tocqueville Asset Management
New York
$391K +$23.5K +81 +7%
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$381K +$38.3K +132 +13%
Simplex Trading
46
Simplex Trading
Illinois
$367K +$284K +979 +809%
Citigroup
47
Citigroup
New York
$321K -$1.13M -3,887 -80%
CS
48
Credit Suisse
Switzerland
$303K +$16.8K +58 +7%
Two Sigma Advisers
49
Two Sigma Advisers
New York
$303K +$29K +100 +12%
CIAS
50
Capital Investment Advisory Services
North Carolina
$294K – – –
1
2
3 4 5

BTAI Hedge Fund Activity: Q1 2022 in Review

96 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q1 2022, worth a combined $274M — down 3.2% from $283M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new BTAI positions and 12 closed out — a net gain of 4 holders — while 34 added to existing stakes and 28 trimmed.

The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $4.86M. The largest seller was AllianceBernstein, cutting an estimated $26.6M.

  • 96 institutional investors held BioXcel Therapeutics (BTAI) as of Q1 2022, up from 93 in Q4 2021.
  • Funds reported $274M of BioXcel Therapeutics stock for Q1 2022, down 3.2% quarter-over-quarter.
  • 16 funds opened new BioXcel Therapeutics positions in Q1 2022 and 12 closed out, a net change of +4 holders.
  • The largest BioXcel Therapeutics buyer in Q1 2022 was Rubric Capital Management (New York), an estimated $4.86M added.
  • The largest BioXcel Therapeutics seller in Q1 2022 was AllianceBernstein, an estimated $26.6M sold.

Based on aggregated 13F filings for Q1 2022.